>>BILLERICA, Mass.--(BUSINESS WIRE)--Jan. 6, 2003--Bruker Daltonics Inc. (NASDAQ: BDAL - News) today reported that new order bookings for its life-science systems grew 22% in the fourth quarter of 2002, compared to Q4 of 2001. For the full year 2002, life-science systems new order bookings also grew 22%, compared to the year 2001.
Frank Laukien, President and Chief Executive Officer, commented: "In the fourth quarter, both our MALDI-TOF product line, which includes our UltraFlex(TM) MALDI-TOF/TOF, and our ion trap product line experienced a strong finish for the year. For the full year 2002, the most significant order growth for our company occurred in MALDI-TOF/TOF, due to the unprecedented information content and sensitivity offered by this novel proteomics technology, as well as in ESI-(Q-q-)TOF orders. Geographically, we are particularly pleased with our growth in the Asia-Pacific region."
"In 2002, nearly 65% of our life-science orders came from universities, medical research institutions, governmental life-science labs and other non-profit institutions, where we expect to see continued strong funding worldwide in 2003. In terms of dollar value, approximately 80% of our life-science systems orders were booked by our direct sales force, while about 20% were booked via our strategic partners and country distributors."<<
Right on schedule. But previous readings have been in the 25% range. Nothing on substance detection, which one might think would be showing something, considering the possibility of war. I'm sure the subject will come up in the earnings CC. Anyhow, this isn't exactly lighting a fire under the stock.
Cheers, Tuck |
